Results 11 to 20 of about 3,235 (226)

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.

New England Journal of Medicine, 2021
BACKGROUND Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell-derived cytokine implicated in the pathogenesis of asthma.
A. Menzies-Gow, J. Corren, A. Bourdin, Geoffrey Chupp, E. Israel, M. Wechsler, C. Brightling, J. Griffiths, A. Hellqvist, K. Bowen, P. Kaur, G. Almqvist, S. Ponnarambil, G. Colice   +13 more
semanticscholar   +5 more sources

Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps. [PDF]

New England Journal of Medicine
BACKGROUND Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and safety in adults with severe, uncontrolled ...
B. Lipworth, Joseph K. Han, M. Desrosiers, Claire Hopkins, Stella E. Lee, J. Mullol, O. Pfaar, Ting Li, Claudia Chen, G. Almqvist, M. Margolis, J. Mclaren, S. Jagadeesh, Jamie Mackay, A. Megally, Å. Hellqvist, V. Mankad, L. Bahadori, S. Ponnarambil   +18 more
semanticscholar   +4 more sources

Tezepelumab in patients with allergic and eosinophilic asthma [PDF]

Allergy, 2023
AbstractAsthma is a heterogeneous disease commonly driven by allergic and/or eosinophilic inflammation, both of which may be present in severe disease. Most approved biologics for severe asthma are indicated for specific phenotypes and target individual downstream type 2 components of the inflammatory cascade.
Marco Caminati, Roland Buhl, Jonathan Corren, Nicola A. Hanania, Harold Kim, Stephanie Korn, Marek Lommatzsch, Neil Martin, Andrea Matucci, Shuaib M. Nasser, Ian D. Pavord, Christian Domingo   +11 more
core   +9 more sources

Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study

Allergology International, 2023
Background: Tezepelumab, a human monoclonal antibody, blocks the activity of thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced exacerbations by 56% compared with placebo in adults and adolescents with severe,
Tamotsu Ishizuka, Andrew Menzies-Gow, Hiroshi Okada, Yasushi Fukushima, Nobuya Hayashi, Gene Colice, Sandhia Ponnarambil, Gillian Hunter, Hiroshi Odajima, Motohiro Ebisawa   +9 more
doaj   +2 more sources

Tezepelumab: First Approval

Drugs, 2022
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine implicated in the pathogenesis of asthma. Tezepelumab (tezepelumab-ekko; TEZSPIRE™) is a first-in-class human IgG2λ monoclonal antibody that inhibits the action of TSLP. Administered subcutaneously, it is being developed by Amgen and AstraZeneca for the treatment of asthma ...
Sheridan M. Hoy (4897468)
openaire   +3 more sources

Positioning of Tezepelumab in Severe Asthma

Journal of Investigational Allergology and Clinical Immunology, 2023
Asthma is one of the most common chronic diseases and is estimated to be severe in 3%-10% of affected patients. There is a need for additional biologic treatments that are highly efficacious across the spectrum of severe uncontrolled asthma. Currently available drugs inhibit 1 or 2 specific cytokines or IgE antibodies and thus only partially suppress ...
J C, Miralles-López, D, Antolín-Amérigo, I, García-Moguel, J, Domínguez-Ortega, J, Delgado-Romero, S, Quirce   +5 more
openaire   +3 more sources

Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma

Allergology International, 2023
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that plays a vital role in the induction of type 2 inflammation via both innate and acquired immune cascades.
Momoko Kurihara, Hiroki Kabata, Misato Irie, Koichi Fukunaga   +3 more
doaj   +2 more sources

Cost-effectiveness of tezepelumab in Canada for severe asthma

Journal of Medical Economics, 2023
To assess the cost-effectiveness of tezepelumab as add-on maintenance therapy compared with standard of care (SoC) for the treatment of patients with severe asthma in Canada. A cost utility analysis was conducted using a Markov cohort model with five health states (“controlled asthma”, “uncontrolled asthma”, “previously controlled asthma with ...
Mara Habash, Hannah Guiang, Irvin Mayers, Anna Quinton, Vivian Vuong, Aidan Dineen, Sumeet Singh, Danny Gibson, Adrian P. Turner   +8 more
openaire   +3 more sources

Tezepelumab treatment in severe asthma with recurrent chronic rhinosinusitis with nasal polyps: Case series

Journal of Allergy and Clinical Immunology: Global
Background: Tezepelumab is a human IgG2 mAb that inhibits thymic stromal lymphopoietin (TSLP) and is approved for treatment of severe asthma. Bronchial asthma, usually a type 2 inflammatory disease, often co-occurs with chronic rhinosinusitis with nasal ...
Yoshiro Kai, MD, PhD
doaj   +2 more sources

Tezepelumab for the Treatment of Chronic Spontaneous Urticaria: Results of the Phase 2b INCEPTION Study.

Journal of Allergy and Clinical Immunology
BACKGROUND Tezepelumab, a monoclonal antibody inhibiting thymic stromal lymphopoietin (TSLP), is an upstream-targeted therapy with potential to inhibit multiple pathways in chronic spontaneous urticaria (CSU). OBJECTIVE To evaluate tezepelumab efficacy
J. Mclaren, Yun Chon, Kevin S. Gorski, J. Bernstein, J. Corren, K. Hayama, V. Jain, Hermenio Lima, H. Sofen, S. Ponnarambil, Nestor A. Molfino, M. Maurer   +11 more
semanticscholar   +2 more sources